^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Merkel Cell Carcinoma |
| Drug: | cavrotolimod (AST-008) (TLR9 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration
Published date:
01/11/2021
Excerpt:
Exicure, Inc...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for its clinical product candidate, cavrotolimod (AST-008), for two development programs..cavrotolimod in combination with anti-programmed death-1 (PD-1) therapy for the treatment of patients with locally advanced or metastatic Merkel cell carcinoma (MCC)...cavrotolimod in combination with anti-PD-1/anti-PD-ligand 1 (anti-PD-(L)1) therapy for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)...
Secondary therapy:
Undisclosed PD-1 inhibitor
